In addition, Mastracci et al. [6] identified that CTLA4 ( +) TILs might represent a marker of the ipilimumab response, alone or with CD3( +)/CD8( +) subsets, and characterized tumor-infiltrating lymphocytes in 40 melanoma lesions from 17 patients treated with ipilimumab. Here, CTLA4 is linked to neoplasm.